In renal cell carcinoma, an mTOR inhibitor has been demonstrated to promote autophagy-mediated RIPK clearance to inhibit necroptosis, but it also exerts a positive role in necroptosis by suppressing Nrf2 nuclear translocation and consequent antioxidant defense. Here, MTOR is linked to renal cell carcinoma.